FOURIER PCSK9 Outcomes Trial to Headline

ACC Conference Reporter

ACC.17 | WASHINGTON, DC — The moment of truth may have already come with positive topline results from the first cardiovascular outcomes trial with a PCSK9 inhibitor, but there's still a cliffhanger or two ahead from FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) as it takes the spotlight at the American College of Cardiology annual meeting here. Read More >>>

Keywords: ACC17, ACC Annual Scientific Session

< Back to Listings